A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

NCT05153564 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide 1.34 mg/mL
DRUG: Semaglutide 3.0 mg/mL
DRUG: NNC0480-0389 10 mg/mL
DRUG: NNC0480-0389 30 mg/mL
DRUG: Microgynon®

Sponsor

Novo Nordisk A/S